Liver Cirrhosis Network: Scientific and Data Coordination Center
Liver Cirrhosis Network: Scientific and Data Coordination Center
批准号:
10309196
负责人:
Jody D. Ciolino
金额:
$239.0万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-08-28 至 2026-07-31
关键词:
Adrenergic beta-AntagonistsAlcohol dependenceAscitesBiometryBlood VesselsBody Weight decreasedBudgetsCase Report FormCause of DeathCell physiologyChargeChronic Hepatitis CCirrhosisClinicalClinical Trials DesignCohort StudiesCommunicationConfusionDataData AnalysesData Coordinating CenterDevelopmentDiseaseDisease ProgressionEndothelial CellsEnzymesEventFacultyFatigueFibrosisGastrointestinal HemorrhageHemorrhageHepaticHepatic EncephalopathyHuman ResourcesIcterusImageImpairmentInflammationInstitutional Review BoardsInterventionInvestigationKidneyLaboratoriesLeadLeadershipLeftLife StyleLinkLiverLiver CirrhosisLiver diseasesLongitudinal cohortMalignant NeoplasmsManualsMedicalMeta-AnalysisMethodologyModificationMonitorMorbidity - disease rateMulti-site clinical studyMulticenter StudiesNational Institute of Diabetes and Digestive and Kidney DiseasesObesityOperative Surgical ProceduresOrganOutcomeOxidative StressOxidoreductasePatientsPositioning AttributePreventive MedicinePrimary carcinoma of the liver cellsPrognosisProspective cohortProteinsProtocols documentationProviderPublic HealthRandomizedRandomized Controlled TrialsReportingReproducibilityResearchResearch DesignResearch PersonnelResourcesRiskRoleSafetySamplingSiteSocial SciencesStatistical Data InterpretationSymptomsTrainingTransplantationUnited StatesUniversitiesWorkabsorptioncentral databaseclinical centercostcurative treatmentsdata qualitydesigndisease natural historydouble-blind placebo controlled trialexperiencegastrointestinalimprovedinfection riskinnovationliver transplantationmembermethod developmentmid-career facultymortalitymultiple data typesnonalcoholic steatohepatitisnovelnutritionoperationpreventprofessorprospectivequality assurancesymptom treatmenttransplant centerstreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Liver cirrhosis poses a significant public health burden in the United States (US) as it is associated with
substantial morbidity, mortality and cost. An estimated one-third of patients develop decompensating events
such as gastrointestinal variceal bleeding, ascites, hepatic encephalopathy (HE), jaundice, and renal impairment.
Further, these poor outcomes are also associated with development of hepatocellular carcinoma (HCC) in the
cirrhotic liver, the ninth leading cause of death among cancers within the US. While transplantation is a curative
treatment for cirrhosis, patients are often ineligible for transplantation due to lack of available organs and
additional risks involved. Thus, patients and providers frequently focus on symptomatic treatment options such
as lifestyle/nutrition modifications to initiate weight loss and optimize protein absorption, nonselective beta-
blockers to reduce the risk of gastrointestinal bleeding, and treatment for HE to improve confusion. A recent
meta-analysis suggests statin therapy as a promising treatment for cirrhosis as statins tend to decrease oxidative
stress and inflammation and increase endothelial cell function, with downstream effects including reduction of
hepatic inflammation, fibrosis, and vascular tone. Although this review represents over 120 thousand patients,
true efficacy data in the setting of a randomized controlled trial (RCT) are presently limited to just four RCTs from
outside of the US, representing less than 300 patients with cirrhosis.
To better understand the natural history of the disease and also to further evaluate the use of statins in the
treatment of cirrhosis, the Liver Cirrhosis Network (LCN), consisting of up to 10 clinical centers (CCs) and one
Scientific and Data Coordination Center (SDCC) will be charged with developing (a) a prospective cohort and
(b) an RCT to evaluate statin efficacy in patients with cirrhosis. Northwestern University Data Analysis and
Coordinating Center (NUDACC) and its partners propose to serve as the SDCC--the central scientific and
leadership core for the LCN--coordinating all operational and data-related activities using cutting-edge resources
for study design, planning and conduct, ongoing monitoring, and statistical analyses. NUDACC unites an
interdisciplinary team with wide-ranging experience including collaborative and methodologic biostatisticians,
hepatologists, data managers, project managers, and multiple supporting study staff. Together we propose to
collaborate with the LCN to lead the design, conduct, coordination, oversight, management, administration,
analyses, and dissemination for the LCN-related studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A double-blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low dose treatment for hypertension (QUARTET USA)
-
批准号:10680465
-
项目类别:
-
资助金额:$54.41万
-
财政年份:2018
-
负责人:Jody D. Ciolino
-
依托单位:
A double-blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low dose treatment for hypertension (QUARTET USA)
-
批准号:10596921
-
项目类别:
-
资助金额:$62.9万
-
财政年份:2018
-
负责人:Jody D. Ciolino
-
依托单位:
A double-blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low-dose treatment for hypertension (QUARTET USA)
-
批准号:10021704
-
项目类别:
-
资助金额:$110.4万
-
财政年份:2018
-
负责人:Jody D. Ciolino
-
依托单位:
海外基金